Abstract
The EPIC study showed that blockade of the platelet surface-membrane glycoprotein IIb/IIIa receptor with abciximab reduced the incidence of acute ischemic events by 35% in patients undergoing high-risk angioplasty. Unfortunately, this benefit was accompanied by an increased incidence of major bleeding. Here, the EPILOG trial investigators examined whether …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
